Spectrum Pharmaceuticals Inc. (NASDAQ:SPPI) shares, rose in value on Friday, August 05, with the stock price up by 5.41% to the previous day’s close as strong demand from buyers drove the stock to $0.99.
Actively observing the price movement in the recent trading, the stock is buoying the session at $0.94, falling within a range of $0.8703 and $0.9396. The value of beta (5-year monthly) is 2.07. Referring to stock’s 52-week performance, its high was $3.25, and the low was $0.60. On the whole, SPPI has fluctuated by 15.83% over the past month.
With the market capitalization of Spectrum Pharmaceuticals Inc. currently standing at about $174.71 million, investors are eagerly awaiting this quarter’s results, scheduled for Mar 28, 2022 – Apr 01, 2022. As a result, investors might want to see an improvement in the stock’s price before the company announces its earnings report. Analysts are projecting the company’s earnings per share (EPS) to be -$0.16, which is expected to increase to -$0.12 for fiscal year -$0.51 and then to about -$0.13 by fiscal year 2023. Data indicates that the EPS growth is expected to be 50.00% in 2023, while the next year’s EPS growth is forecast to be 74.50%.
Revisions could be a useful indicator to get insight on short-term price movement; so for the company, there were no upward and no downward review(s) in last seven days. We see that SPPI’s technical picture suggests that short-term indicators denote the stock is a Hold on average. However, medium term indicators have put the stock in the category of 50% Sell while long term indicators on average have been pointing out that it is a Hold.
5 analyst(s) have assigned their ratings of the stock’s forecast evaluation on a scale of 1.00-5.00 to indicate a strong buy to a strong sell recommendation. The stock is rated as a Hold by 1 analyst(s), 4 recommend it as a Buy and 0 called the SPPI stock Overweight. In the meantime, 0 analyst(s) believe the stock as Underweight and 0 think it is a Sell. Thus, investors eager to increase their holdings of the company’s stock will have an opportunity to do so as the average rating for the stock is Buy.
The stock’s technical analysis shows that the PEG ratio is about 0, with the price of SPPI currently trading nearly 17.31% and 20.53% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 70.85, while the 7-day volatility ratio is showing 6.93% which for the 30-day chart, stands at 6.19%. Furthermore, Spectrum Pharmaceuticals Inc. (SPPI)’s beta value is 2.05, and its average true range (ATR) is 0.05. The company’s stock has been forecasted to trade at an average price of $5.60 over the course of the next 52 weeks, with a low of $3.00 and a high of $10.00. Based on these price targets, the low is -203.03% off current price, whereas the price has to move -910.1% to reach the yearly target high. Additionally, analysts’ median price of $4.00 is likely to be welcomed by investors because it represents a decrease of -304.04% from the current levels.
A comparison of Spectrum Pharmaceuticals Inc. (SPPI) with its peers suggests the former has fared considerably weaker in the market. SPPI showed an intraday change of 5.41% in today’s session so far, and over the past year, it shrunk by -70.11%%. In comparison, Biogen Inc. (BIIB) has moved higher at 0.10% today and is down -35.73% over the past 12 months. On the other hand, the price of Johnson & Johnson (JNJ) has fallen -0.90% today. The stock, however, is off -0.91% from where it was a year ago. Additionally, there is a loss of -0.24% for Bristol-Myers Squibb Company (BMY) in recent trading while the stock has seen an overall depriciation of 5.30%% over the past year. Other than that, the overall performance of the S&P 500 during the today’s session so far shows that it lost -0.35%. Meanwhile, the Dow Jones Industrial Slipped by -0.16%.
Data on historical trading for Spectrum Pharmaceuticals Inc. (NASDAQ:SPPI) indicates that the trading volumes over the past 10 days have averaged 1.32 million and over the past 3 months, they’ve averaged 2.01 million. According to company’s latest data on outstanding shares, there are 169.74 million shares outstanding.
Nearly 1.90% of Spectrum Pharmaceuticals Inc.’s shares belong to company insiders and institutional investors own 40.30% of the company’s shares. The data on short interest also indicates that stock shorts accounted for 5.55 million shares as on Jul 14, 2022, resulting in a short ratio of 2.09. According to the data, the short interest in Spectrum Pharmaceuticals Inc. (SPPI) stood at 3.08% of shares outstanding as of Jul 14, 2022; the number of short shares registered in Jun 14, 2022 reached 11.89 million. The stock has fallen by -26.32% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the SPPI stock heading into the next quarter.